Physician profile
Mark P Miller
NPI 1073575353
$31,927.48
in general payments reported to CMS, 2019-2025
38 companies · $416 in 2025
The $416 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $8,349 · 2021: $3,177 · 2022: $1,317 · 2023: $542 · 2024: $53.47 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,011.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $10,797.62 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $6,833.90 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $5,566.04 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $999.98 | 2019-2022 | |
| Pfizer INC. | $690.33 | 2019-2025 | |
| Edwards Lifesciences Corporation | $687.50 | 2019 | |
| Amgen INC. | $671.91 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $509.11 | 2019-2023 | Mitraclip |
| Sanofi-Aventis U.S. LLC | $502.72 | 2019-2021 | |
| Cvrx, INC. | $501.97 | 2022-2023 | Barostim Neo System |
| Regeneron Healthcare Solutions, INC. | $452.83 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $425.35 | 2019-2021 | |
| Biotronik INC. | $363.27 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $341.56 | 2022-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $309.66 | 2019-2025 | Lifevest |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.